← back to search

Marco Giaisi

German Cancer Research Center · DE
Area of research
Molecular Biology · Immunology
Research interest
Research interests include NF-κB Signaling Pathways, DNA Repair Mechanisms, Cell death mechanisms and regulation, and Immune Cell Function and Interaction.
h-index
29
citations
2,430
works
43
NIH funding
primary concept
email

Recent publications

Recurrent DNA break clusters drive replication-stress-induced copy number variants and genome diversification
Nature Communications 2026cited by 2position: middledoi
Strand-resolved mutagenicity of DNA damage and repair
Nature 2024cited by 40position: middledoi
Linear interaction between replication and transcription shapes DNA break dynamics at recurrent DNA break Clusters
Nature Communications 2024cited by 12position: middledoi
Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model
Cancer Letters 2016cited by 31position: middledoi
The anticancer phytochemical rocaglamide inhibits Rho GTPase activity and cancer cell migration
Oncotarget 2016cited by 27position: middledoi
Mangrove dolabrane‐type of diterpenes tagalsins suppresses tumor growth <i>via</i><scp>ROS</scp>‐mediated apoptosis and <scp>ATM/ATR–C</scp>hk1/Chk2‐regulated cell cycle arrest
International Journal of Cancer 2015cited by 32position: middledoi
HTLV‐1‐associated adult <scp>T</scp> cell leukemia is highly susceptible to <scp>N</scp>avitoclax due to enhanced <scp>B</scp>ax expression
International Journal of Cancer 2015cited by 14position: middledoi
Targeting CDK9 by wogonin and related natural flavones potentiates the anti‐cancer efficacy of the Bcl‐2 family inhibitor ABT‐263
International Journal of Cancer 2014cited by 61position: middledoi
Tax contributes apoptosis resistance to HTLV-1-infected T cells via suppression of Bid and Bim expression
Cell Death and Disease 2014cited by 38position: middledoi
The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints
International Journal of Cancer 2013cited by 33position: middledoi
The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation‐induced cell death in leukemic T cells
International Journal of Cancer 2013cited by 12position: middledoi
The Natural Anticancer Compounds Rocaglamides Inhibit the Raf-MEK-ERK Pathway by Targeting Prohibitin 1 and 2
Chemistry & Biology 2012cited by 159position: middledoi
Curcumin Suppresses T Cell Activation by Blocking Ca2+ Mobilization and Nuclear Factor of Activated T Cells (NFAT) Activation
Journal of Biological Chemistry 2012cited by 51position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Rebecca Köhler · University of Utah10 papers (2012–2016)Min Li‐Weber · German Cancer Research Center9 papers (2012–2016)Peter H. Krammer · Slovak Academy of Sciences9 papers (2012–2016)Jennifer Neumann · University of North Carolina at Chapel Hill3 papers (2012–2015)Wolfgang W. Müller · German Cancer Research Center2 papers (2012–2014)Gernot Polier · Daiichi Sankyo (Germany)2 papers (2012–2014)Lorenzo Corazzi · German Cancer Research Center2 papers (2024–2026)Giulia Di Muzio · German Cancer Research Center2 papers (2024–2026)Pei‐Chi Wei · Boston Children's Hospital2 papers (2024–2026)Mathias Witzens‐Harig · Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie2 papers (2015–2015)Vivien Ionasz · German Cancer Research Center2 papers (2024–2026)Boyu Ding · Jiangsu University2 papers (2024–2026)Anna Marx · German Cancer Research Center2 papers (2024–2026) · 1 papers (2016–2016)Wenhan Lin · Ningbo University1 papers (2015–2015)Sergej Andrejev · Institute of Cancer Research1 papers (2024–2024)Paul Markus Müller · University of Tübingen1 papers (2016–2016)Melanie Boerries · University of Freiburg1 papers (2013–2013) · 1 papers (2012–2012)Sarah Benedetto · German Cancer Research Center1 papers (2026–2026)